S10 Ep13: FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced/Metastatic Urothelial Carcinoma

Dr Galsky discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer, key efficacy and safety data from the EV-302 trial, and future directions in urothelial cancer research.